Nitrofurantoin induced interstitial lung disease
نویسندگان
چکیده
منابع مشابه
Drug Induced Interstitial Lung Disease
With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD) can be caused by chemotherapeutic agents,...
متن کاملTimolol-induced interstitial lung disease
Timolol maleate is a non-selective beta-adrenergic receptor blocking agent with demonstrated efficacy in the treatment of open-angle glaucoma. A 76 year old female who presented with productive cough, progressive dyspnea and hypoxia after starting timolol maleate opthalamic drops following glaucoma surgery. The patient was diagnosed with interstitial lung disease secondary to timolol treatment ...
متن کاملNitrofurantoin-induced lung- and hepatotoxicity.
We present the case of a patient referred to the gastroenterology service for investigation of abnormal liver function tests. She had been taking nitrofurantoin for 16 months as prophylaxis against urinary tract infections. CT scan showed evidence of lung pneumonitis and low attenuation in the liver parenchyma. Nitrofurantoin-induced pneumonitis and hepatotoxicity was diagnosed. The patient res...
متن کاملInfluenza vaccine-induced interstitial lung disease.
typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol 2010; 48: 4177– 4185. 3 Wagner KS, White JM, Lucenko I, et al. Diphtheria in the postepidemic period, Europe, 2000–2009. Emerg Infect Dis 2012; 18: 217–225. 4 Wilson AP. The return of Corynebacterium diphtheriae: the rise of nontoxigenic strains. J Hosp Infect 1995; 30: Suppl....
متن کاملRecurrent gefitinib-induced interstitial lung disease.
Gefitinib, the epidermal growth factor receptor tyrosine kinase inhibitor, is effective for patients with non-small cell lung cancer. However, a serious adverse effect, interstitial lung disease (ILD), has been reported. The re-administration of gefitinib might be considered when there is no other choice of treatment and a therapeutic effect can be expected; however, there is no published data ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Nephrology
سال: 2014
ISSN: 0971-4065
DOI: 10.4103/0971-4065.143302